Multiple Sclerosis Research Today is a free monthly online journal that collates and summarizes the latest research about Multiple Sclerosis, including details on diagnosis, symptoms, treatment, prognosis.

Volume 8 (2011), Issue 5 (May)

1. Quality of life of multiple sclerosis patients with comorbid migraine.
   Neurol Sci, 32: S149-51. [Abstract] [Full-text]
2. Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up.
   J Rehabil Med, 43(6): 511-4. [Abstract] [Full-text]
3. Multiple sclerosis, idiopathic dilated cardiomyopathy, and insulin-dependent diabetes mellitus: a common mechanism of irregular immune regulation.
   Neurologist, 17(3): 172-5. [Abstract] [Full-text]
4. Cognition in multiple sclerosis.
   Curr Opin Neurol, 24(3): 244-9. [Abstract] [Full-text]
5. Experimental models of multiple sclerosis.
   Curr Opin Neurol, 24(3): 291-9. [Abstract] [Full-text]
6. Multiple sclerosis: current treatment algorithms.
   Curr Opin Neurol, 24(3): 230-7. [Abstract] [Full-text]
7. Risks and benefits of multiple sclerosis therapies: need for continual assessment?
   Curr Opin Neurol, 24(3): 238-43. [Abstract] [Full-text]
8. Challenges to clinical trials in multiple sclerosis: outcome measures in the era of disease-modifying drugs.
   Curr Opin Neurol, 24(3): 255-61. [Abstract] [Full-text]
9. Functional treatments in multiple sclerosis.
   Curr Opin Neurol, 24(3): 250-4. [Abstract] [Full-text]
10. Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications.
    Curr Opin Neurol, 24(3): 224-9. [Abstract] [Full-text]
11. Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1/M23 isoforms and orthogonal arrays.
    J Biol Chem, 286(18): 16516-24. [Abstract] [Full-text]
12. The level of isoprostanes as a non-invasive marker for in vivo lipid peroxidation in secondary progressive multiple sclerosis.
    Neurochem Res, 36(6): 1012-6. [Abstract] [Full-text]
13. A population-based study of neuromyelitis optica in Caucasians.
    Neurology, 76(18): 1589-95. [Abstract] [Full-text]
14. Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing-remitting course of disease and after clinical isolated syndrome.
    Neurol Res, 33(4): 415-20. [Abstract] [Full-text]
15. MRI correlates of cognitive impairment in childhood-onset multiple sclerosis.
    Neuropsychology, 25(3): 319-32. [Abstract] [Full-text]
16. Vitamin D levels in Swiss multiple sclerosis patients.
    Swiss Med Wkly, 141: w13192. [Abstract] [Full-text]
17. THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
    Expert Rev Neurother, 11(5): 627-37. [Abstract] [Full-text]
18. Social cognitive correlates of physical activity in inactive adults with multiple sclerosis.
    Int J Rehabil Res, 34(2): 115-20. [Abstract] [Full-text]
19. Choice of psychological coping in laryngectomized, head and neck squamous cell carcinoma patients versus multiple sclerosis patients.
    Eur Arch Otorhinolaryngol, 268(6): 907-15. [Abstract] [Full-text]
20. Structure of HLA-A*0301 in complex with a peptide of proteolipid protein: insights into the role of HLA-A alleles in susceptibility to multiple sclerosis.
    Acta Crystallogr D Biol Crystallogr, 67: 447-54. [Abstract] [Full-text]
21. Visual acuity is associated with performance on visual and non-visual neuropsychological tests in multiple sclerosis.
    Clin Neuropsychol, 25(4): 640-51. [Abstract] [Full-text]
22. Depression in multiple sclerosis: reactive or endogenous?
    Clin Neuropsychol, 25(4): 624-39. [Abstract] [Full-text]
23. The genetic association of variants in CD6, TNFRSF1A and IRF8 to multiple sclerosis: a multicenter case-control study.
    PLoS One, 6(4): e18813. [Abstract] [Full-text]
24. Target populations for first-in-human embryonic stem cell research in spinal cord injury.
    Cell Stem Cell, 8(5): 468-75. [Abstract] [Full-text]
25. Longitudinal measurement invariance of the Multiple Sclerosis Walking Scale-12.
    J Neurol Sci, 305(1): 75-9. [Abstract] [Full-text]
26. Biomarkers of disease activity in multiple sclerosis.
    J Neurol Sci, 305(1): 1-10. [Abstract] [Full-text]
27. Quantitative measures detect sensory and motor impairments in multiple sclerosis.
    J Neurol Sci, 305(1): 103-11. [Abstract] [Full-text]
28. Change in PASAT performance correlates with change in P3 ERP amplitude over a 12-month period in multiple sclerosis patients.
    J Neurol Sci, 305(1): 45-52. [Abstract] [Full-text]
29. Vitamin D metabolic pathway genes and risk of multiple sclerosis in Canadians.
    J Neurol Sci, 305(1): 116-20. [Abstract] [Full-text]
30. Geography of hospital admissions for multiple sclerosis in England and comparison with the geography of hospital admissions for infectious mononucleosis: a descriptive study.
    J Neurol Neurosurg Psychiatry, 82(6): 682-7. [Abstract] [Full-text]
31. Long-term follow-up of pediatric patients treated with mitoxantrone for multiple sclerosis.
    Neuropediatrics, 42(1): 7-12. [Abstract] [Full-text]
32. Acquired pendular nystagmus in multiple sclerosis and oculopalatal tremor.
    Neurology, 76(19): 1650-7. [Abstract] [Full-text]
33. Development of anti-CD20 therapy for multiple sclerosis.
    Exp Cell Res, 317(9): 1312-8. [Abstract] [Full-text]
34. A critical appraisal of treatment decisions in multiple sclerosis--old versus new.
    Nat Rev Neurol, 7(5): 255-62. [Abstract] [Full-text]
35. Managing MS in a changing treatment landscape.
    J Neurol, 258(5): 728-39. [Abstract] [Full-text]
36. Beta-interferon for multiple sclerosis.
    Exp Cell Res, 317(9): 1301-11. [Abstract] [Full-text]
37. Impact of fatigue on the efficacy of rehabilitation in multiple sclerosis.
    J Neurol, 258(5): 835-9. [Abstract] [Full-text]
38. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
    J Neurol, 258(5): 882-8. [Abstract] [Full-text]
39. One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients.
    J Neurol, 258(5): 895-903. [Abstract] [Full-text]
40. Occurrence of neuronal dysfunction during the first 5 years of multiple sclerosis is associated with cognitive deterioration.
    J Neurol, 258(5): 811-9. [Abstract] [Full-text]
41. Evaluation of health-related quality of life, fatigue and depression in neuromyelitis optica.
    Eur J Neurol, 18(6): 836-41. [Abstract] [Full-text]
42. Assessment of gait parameters and fatigue in MS patients during inpatient rehabilitation: a pilot trial.
    J Neurol, 258(5): 889-94. [Abstract] [Full-text]
43. Improving the characterization of radiologically isolated syndrome suggestive of multiple sclerosis.
    PLoS One, 6(4): e19452. [Abstract] [Full-text]
44. Motor callosal disconnection in early relapsing-remitting multiple sclerosis.
    Hum Brain Mapp, 32(6): 846-55. [Abstract] [Full-text]
45. Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis.
    J Neuroimmunol, 234(1): 155-60. [Abstract] [Full-text]
46. Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited: an ongoing story.
    J Neuroimmunol, 234(1): 1-6. [Abstract] [Full-text]
47. Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms.
    J Neuroimmunol, 234(1): 7-18. [Abstract] [Full-text]
48. Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells.
    J Neuroimmunol, 234(1): 148-54. [Abstract] [Full-text]
49. Clonal composition of neuroantigen-specific CD8+ and CD4+ T-cells in multiple sclerosis.
    J Neuroimmunol, 234(1): 131-40. [Abstract] [Full-text]
50. Disease-associated inflammatory biomarker profiles in blood in different subtypes of multiple sclerosis: prospective clinical and MRI follow-up study.
    J Neuroimmunol, 234(1): 141-7. [Abstract] [Full-text]
51. Temporal dynamics of cerebrospinal fluid anti-aquaporin-4 antibodies in patients with neuromyelitis optica spectrum disorders.
    J Neuroimmunol, 234(1): 124-30. [Abstract] [Full-text]
52. Urinary diversion/reconstruction for cases of catheter intolerant secondary progressive multiple sclerosis with refractory urinary symptoms.
    J Urol, 185(6): 2201-6. [Abstract] [Full-text]
53. Quality of life in multiple sclerosis patients with urinary disorders: reliability and validity of the Turkish version of King's Health Questionnaire.
    Neurol Sci, 32(3): 417-21. [Abstract] [Full-text]
54. Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer's disease.
    J Neural Transm, 118(5): 747-52. [Abstract] [Full-text]
55. Aquaporin-4 Mz isoform: brain expression, supramolecular assembly and neuromyelitis optica antibody binding.
    Glia, 59(7): 1056-63. [Abstract] [Full-text]
56. What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta-analysis of the literature.
    BJOG, 118(7): 790-7. [Abstract] [Full-text]
57. Glatiramer acetate could be a hypothetical therapeutic agent for neuromyelitis optica.
    Med Hypotheses, 76(6): 820-2. [Abstract] [Full-text]
58. The expression of VEGF-A is down regulated in peripheral blood mononuclear cells of patients with secondary progressive multiple sclerosis.
    PLoS One, 6(5): e19138. [Abstract] [Full-text]
59. Value of MR venography for detection of internal jugular vein anomalies in multiple sclerosis: a pilot longitudinal study.
    AJNR Am J Neuroradiol, 32(5): 938-46. [Abstract] [Full-text]
60. Voxelwise assessment of the regional distribution of damage in the brains of patients with multiple sclerosis and fatigue.
    AJNR Am J Neuroradiol, 32(5): 874-9. [Abstract] [Full-text]
61. A case of multiple sclerosis presenting with inflammatory cortical demyelination.
    Neurology, 76(20): 1705-10. [Abstract] [Full-text]
62. The Multiple Sclerosis Self-Management Scale: revision and psychometric analysis.
    Rehabil Psychol, 56(2): 150-9. [Abstract] [Full-text]
63. Improvements in partner support predict sexual satisfaction among individuals with multiple sclerosis.
    Rehabil Psychol, 56(2): 117-22. [Abstract] [Full-text]
64. Interaction of HLA-DRB1*1501 allele and TNF-alpha -308 G/A single nucleotide polymorphism in the susceptibility to multiple sclerosis.
    Clin Immunol, 139(3): 277-81. [Abstract] [Full-text]
65. Quantitative assessment of the cervical spinal cord damage in neuromyelitis optica using diffusion tensor imaging at 3 Tesla.
    J Magn Reson Imaging, 33(6): 1312-20. [Abstract] [Full-text]
66. Dual-temporal resolution dynamic contrast-enhanced MRI protocol for blood-brain barrier permeability measurement in enhancing multiple sclerosis lesions.
    J Magn Reson Imaging, 33(6): 1291-300. [Abstract] [Full-text]
67. Neural precursors exhibit distinctly different patterns of cell migration upon transplantation during either the acute or chronic phase of EAE: a serial MR imaging study.
    Magn Reson Med, 65(6): 1738-49. [Abstract] [Full-text]
68. Vitamin D receptor gene polymorphisms in multiple sclerosis patients in northwest Greece.
    J Negat Results Biomed, 10: 3. [Abstract] [Full-text]
69. Natalizumab and HSV meningitis.
    J Neurovirol, 17(3): 288-90. [Abstract] [Full-text]
70. Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: an application in multiple sclerosis.
    Stat Med, 30(13): 1528-40. [Abstract] [Full-text]
71. Comparison of retinal nerve fiber layer and central macular thickness measurements among five different optical coherence tomography instruments in patients with multiple sclerosis and optic neuritis.
    J Neuroophthalmol, 31(2): 110-6. [Abstract] [Full-text]
72. Further evaluation of the Motivational Model of Pain Self-Management: coping with chronic pain in multiple sclerosis.
    Ann Behav Med, 41(3): 391-400. [Abstract] [Full-text]
73. Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis.
    PLoS One, 6(5): e19262. [Abstract] [Full-text]
74. MR imaging of multiple sclerosis.
    Radiology, 259(3): 659-81. [Abstract] [Full-text]
75. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Lancet Neurol, 10(6): 520-9. [Abstract] [Full-text]
76. GSK3β genetic variability in patients with Multiple Sclerosis.
    Neurosci Lett, 497(1): 46-8. [Abstract] [Full-text]
77. Late onset multiple sclerosis.
    Neurologia, 26(5): 291-6. [Abstract] [Full-text]
78. Vitamin D in African Americans with multiple sclerosis.
    Neurology, 76(21): 1824-30. [Abstract] [Full-text]
79. In vivo evidence of disseminated subpial T2* signal changes in multiple sclerosis at 7 T: a surface-based analysis.
    Neuroimage, 57(1): 55-62. [Abstract] [Full-text]
80. High resolution spectral domain optical coherence tomography (SD-OCT) in multiple sclerosis: the first follow up study over two years.
    PLoS One, 6(5): e19843. [Abstract] [Full-text]
81. A new myelin protein, TPPP/p25, reduced in demyelinated lesions is enriched in cerebrospinal fluid of multiple sclerosis.
    Biochem Biophys Res Commun, 409(1): 137-41. [Abstract] [Full-text]
82. Migration and multiple sclerosis in immigrants to Australia from United Kingdom and Ireland: a reassessment. I. Risk of MS by age at immigration.
    J Neurol, 258(6): 1140-9. [Abstract] [Full-text]
83. Religiosity and its relation to quality of life in primary caregivers of patients with multiple sclerosis: a case study in Greece.
    J Neurol, 258(6): 1114-9. [Abstract] [Full-text]
84. Predictors of quality of life in carers for people with a progressive neurological illness: a longitudinal study.
    Qual Life Res, 20(5): 703-11. [Abstract] [Full-text]
85. Transduced B cells: B is for 'beneficial'!
    Eur J Immunol, 41(6): 1528-30. [Abstract] [Full-text]
86. Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients.
    J Transl Med, 9: 42. [Abstract] [Full-text]
87. Bipolar disorder and resembling special psychopathological manifestations in multiple sclerosis: a review.
    Curr Opin Psychiatry, 24(4): 336-40. [Abstract] [Full-text]
88. Quantifying gait impairment in multiple sclerosis using GAITRite technology.
    Gait Posture, 34(1): 145-7. [Abstract] [Full-text]
89. B cells in spontaneous autoimmune diseases of the central nervous system.
    Mol Immunol, 48(11): 1332-7. [Abstract] [Full-text]
90. Variation in NOD2 augments Th2- and Th17 responses to myelin basic protein in multiple sclerosis.
    PLoS One, 6(5): e20253. [Abstract] [Full-text]
91. Development of oral immunomodulatory agents in the management of multiple sclerosis.
    Drug Des Devel Ther, 5: 255-74. [Abstract] [Full-text]
92. Stress and the risk of multiple sclerosis.
    Neurology, 76(22): 1866-71. [Abstract] [Full-text]
93. Restless legs syndrome in multiple sclerosis.
    Eur Neurol, 65(5): 302-6. [Abstract] [Full-text]
94. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.
    Neurology, 76(22): 1858-65. [Abstract] [Full-text]
95. Revealing the genetic basis of multiple sclerosis: are we there yet?
    Curr Opin Genet Dev, 21(3): 317-24. [Abstract] [Full-text]

© 2004-2012 Multiple Sclerosis Research Today. All Rights Reserved.